Why Is Argenx (ARGX) Stock Up Today? A Myositis Trial With No Rival Drug

TL;DR

• Argenx (ARGX) shares were up roughly 11% in thin premarket trading Monday, from Friday's $851.29 close toward the $945-948 range as of about 8:20am ET. Premarket volume on this name ran only in the thousands of shares, well before the 9:30am ET open where the real price discovery happens.
• The catalyst: the Phase 3 ALKIVIA trial hit its primary endpoint. Efgartigimod (sold as VYVGART Hytrulo) beat placebo by 15.4 points on the Total Improvement Score at Week 52 in a combined population of two autoimmune myositis subtypes, p=0.0011.
• The IMNM subgroup result is the more unusual one. Immune-mediated necrotizing myopathy has no FDA-approved treatment today, and this is the first Phase 3 trial to clear a statistically significant bar there: a 14.8-point gain, p=0.0048.
• The dermatomyositis subgroup did not clear significance on its own: a similarly sized 14.5-point gain came in at p=0.1093, likely underpowered on a smaller patient count within that arm rather than a clean miss.
• Argenx has zero prior coverage on this site, despite VYVGART already being an approved franchise in generalized myasthenia gravis, CIDP and ITP. Myositis would be a fourth major indication built on the same FcRn-blocking mechanism.

The Board

Two of three prespecified populations cleared the bar. The one that didn't is the smaller one, not the sicker one.

Why Is Argenx Stock Up Today?

Argenx announced positive topline results from its Phase 3 ALKIVIA trial before Monday's open, and the stock jumped in premarket trading on the news. In the combined population of immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) patients, efgartigimod produced a mean Total Improvement Score of 47.95 at Week 52 against 32.56 for placebo, a 15.4-point gap with p=0.0011. That comfortably clears the conventional 0.05 significance bar, and separation from placebo reportedly emerged as early as Week 4 and held through the full year of dosing, including while patients were tapering off steroids.

Shares were quoted around $945 to $948 in premarket trading as of roughly 8:20am ET, against Friday's $851.29 close, a move in the neighborhood of 11%. That number moved during the time I was writing this: an earlier premarket read put it closer to 6.6%, right after the release hit the wires, before it kept climbing toward the open. Both figures reconcile against the same $851.29 prior close, they're just different minutes of a thin, still-moving premarket tape. Take the percentage as directional until the regular session opens at 9:30am ET.

Argenx Already Owns This Mechanism

Argenx already has an approved drug built on this exact mechanism. VYVGART and VYVGART Hytrulo block the neonatal Fc receptor (FcRn), which cuts circulating levels of the antibodies that drive several autoimmune diseases, and the company has already turned that single mechanism into approvals in generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenia (ITP). Myositis is the next indication in that expansion, and it is a bigger swing than the earlier ones in one specific way: IMNM has no FDA-approved therapy today. Patients currently get steroids, IVIG and steroid-sparing immunosuppressants off-label, with B-cell-depleting drugs like rituximab reserved for refractory cases. None of that carries an FDA label for the disease itself.

Dermatomyositis is a different story on the approval side. Octapharma's IVIG product Octagam 10% won FDA approval for adult dermatomyositis in 2021 off the Phase 3 ProDERM trial, so efgartigimod would be entering a market that already has one approved option rather than none. That is still a real opportunity, an FcRn blocker with a different mechanism and dosing profile than IVIG is a legitimate second choice, but it is not the same white space that IMNM represents.

The Number That Didn't Clear

Worth stating plainly, because the press release will not lead with it: the dermatomyositis subgroup missed statistical significance on its own, at p=0.1093 against a 14.5-point gain that looks, on its face, similar in size to the two populations that did clear the bar. The most likely explanation is a smaller patient count within that specific subgroup diluting statistical power. The point estimate itself lines up with the other two groups, which argues against a fundamentally different drug response. But "most likely" is doing real work in that sentence. Until argenx or an FDA review discusses the DM subgroup analysis in more detail, I'd treat the DM claim as directionally supportive rather than proven on its own terms.

Is ARGX a Buy?

I'd separate the trial result from the stock's reaction to it, because they're not the same question.

The trial result is a genuine positive for the underlying franchise. Argenx is not a single-shot biotech betting the company on one binary readout, it already has three approved indications generating real revenue on this mechanism, and myositis extends the same playbook into a disease with meaningfully unmet need in one of its two main subtypes. A company that keeps successfully expanding one validated mechanism into new indications is a different risk profile than most of the FDA-decision previews this site covers, where the entire investment case rides on a single unproven trial.

The stock's reaction is harder to defend at face value. An 11% premarket pop on thin volume, ahead of the regular session, is not a price I would chase without seeing where it settles once real volume shows up at 9:30am ET. No BLA filing timeline was given in the release, detailed data won't be presented until an unspecified future medical meeting, and the DM subgroup miss is the kind of detail a rushed premarket rally tends to skip past. None of that makes the trial data less real. It does mean today's exact percentage gain is a worse entry point than whatever price this settles at once the market has had a full session to digest both the win and its caveats.

My read: this is a legitimate positive catalyst for a company whose core mechanism keeps working across indications, and I'd treat it as a known franchise having a good quarter rather than a fresh discovery story. I'd rather see how the stock trades once the DM caveat and the missing filing timeline get priced in than buy the premarket gap.

The Options Angle

I don't have a live, sourced ARGX option chain for this premarket session, and I'm not going to price a structure against numbers that aren't checkable. There also isn't a clean dated catalyst to trade into here the way there is with a PDUFA date: myositis data has already read out, and argenx hasn't given a filing timeline that would anchor a follow-up options play the way Ultragenyx's August 23 PDUFA date or Zymeworks' August 25 decision do. Buying options into an already-released catalyst, on a stock already up double digits premarket, is paying for volatility after the event that would have justified it has already happened. This pass gets logged the same way every play on this site does, in the Track Record ledger.

Trade log

#	Stance	Structure	Strikes and expiry	Cost or credit	Spot at writing	Implied move	Conviction	Breakeven
1	Pass	Any directional options structure on the premarket move	N/A	Pricing not sourced this session	~$945-948 premarket (Aug 17, ~8:20am ET) vs $851.29 Friday close	Not sourced	4/10	N/A

The One-Line Read

Argenx's mechanism cleared a bar in a disease with no approved drug. The stock's premarket pop is getting ahead of a DM subgroup miss and a filing timeline nobody has given yet.